@article{oai:nagoya.repo.nii.ac.jp:00022971, author = {Kanda, Mitsuro and Shimizu, Dai and Fujii, Tsutomu and Tanaka, Haruyoshi and Shibata, Masahiro and Iwata, Naoki and Hayashi, Masamichi and Kobayashi, Daisuke and Tanaka, Chie and Yamada, Suguru and Nakayama, Goro and Sugimoto, Hiroyuki and Koike, Masahiko and Fujiwara, Michitaka and Kodera, Yasuhiro}, issue = {3}, journal = {International Journal of Oncology}, month = {Sep}, note = {Identification of novel gastric cancer (GC)-related molecules is necessary to improve management of patients with GC in both diagnostic and therapeutic aspects. The aim of the present study was to determine whether protein arginine methyltransferase 5 (PRMT5) acts as an oncogene in the progression of GC and whether it serves as a novel diagnostic marker and therapeutic target. We conducted global expression profiling of GC cell lines and RNA interference experiments to evaluate the effect of PRMT5 expression on the phenotype of GC cells. We analysed tissues of 179 patients with GC to assess the association of PRMT5 mRNA levels with clinicopathological factors. Differential expression of PRMT5 mRNA by GC cell lines correlated positively with the levels of GEMIN2, STAT3 and TGFB3. PRMT5 knockdown reduced the proliferation, invasion and migration of a GC cell line. PRMT5 mRNA levels were significantly higher in GC tissues than the corresponding adjacent normal tissues and were independent of tumour depth, differentiation and lymph node metastasis. High PRMT5 expression was an independent risk factor of positive peritoneal lavage cytology (odds ratio 3.90, P=0.003) and decreased survival. PRMT5 enhances the malignant phenotype of GC cell lines and its expression in gastric tissues may serve as a biomarker for patient stratification and a potential target of therapy.}, pages = {1195--1202}, title = {Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer}, volume = {49}, year = {2016} }